AnaptysBio, Inc. (ANAB)
NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
| 前收市價 | 17.96 |
| 開市 | 17.96 |
| 買盤 | 17.63 x 800 |
| 賣出價 | 17.65 x 800 |
| 今日波幅 | 17.46 - 18.14 |
| 52 週波幅 | 16.51 - 32.44 |
| 成交量 | |
| 平均成交量 | 263,677 |
| 市值 | 467.999M |
| Beta 值 (5 年，每月) | -0.15 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.06 |
| 業績公佈日 | 2023年11月06日 - 2023年11月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 29.75 |
BenzingaAnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
AnaptysBio Inc (NASDAQ: ANAB) - GSK plc (NYSE: GSK) partnered PERLA head-to-head trial of Jemperli vs. Keytruda for metastatic non-squamous non-small cell lung cancer, met its primary endpoint of objective response rate (ORR). GSK expects to present full results from the PERLA trial, including the primary endpoint of ORR and the key secondary endpoint of progression-free survival, with results by programmed death ligand-1 (PD-L1) expression subgroups, at an upcoming scientific meeting. The trial
